Provided by Tiger Trade Technology Pte. Ltd.

Genmab A/S

36.05
-0.6000-1.64%
Post-market: 36.04-0.0100-0.03%19:30 EDT
Volume:4.30M
Turnover:153.51M
Market Cap:22.17B
PE:28.50
High:36.29
Open:36.18
Low:35.09
Close:36.65
52wk High:40.17
52wk Low:23.62
Shares:615.00M
Float Shares:576.00M
Volume Ratio:0.61
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.27
EPS(LYR):1.54
ROE:14.00%
ROA:8.79%
PB:3.72
PE(LYR):23.45

Loading ...

BNP Paribas Initiates Genmab at Outperform, With $40 Price Target

MT Newswires Live
·
Aug 12

Genmab A/S Stock Falls Monday, Underperforms Market

Dow Jones
·
Aug 11

Genmab A/S Stock Rises Friday, Outperforms Market

Dow Jones
·
Aug 08

Genmab price target raised to $42 from $40 at Guggenheim

TIPRANKS
·
Aug 07

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (GMAB), Cytokinetics (CYTK) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Aug 07

Analysts Are Bullish on Top Healthcare Stocks: Genmab (GMAB), Sotera Health (SHC)

TIPRANKS
·
Aug 07

Genmab raises FY26 revenue view to $4.325B-$4.525B from $4.065B-$4.395B

TIPRANKS
·
Aug 06

Press Release: Genmab Announces Financial Results for the First Half of 2026

Dow Jones
·
Aug 06

Genmab A/S Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Aug 06

Genmab Opens New Front in Solid Tumor Battle With GEN1119 Phase 1 Trial

TIPRANKS
·
Aug 05

Genmab A/S Expected to Post Earnings of 34 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Genmab A/S Stock Falls Monday, Underperforms Market

Dow Jones
·
Aug 04

Genmab A/S Stock Rises Friday, Outperforms Market

Dow Jones
·
Aug 01

Earning Preview: Genmab A/S Q2 revenue is expected to increase by 24.09%, and institutional views are positive

Earnings Agent
·
Jul 31

Genmab A/S Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Jul 30

Genmab A/S Stock Rises Monday, Outperforms Market

Dow Jones
·
Jul 28

Genmab A/S Stock Falls Friday, Underperforms Market

Dow Jones
·
Jul 25

Stocks to Watch: Intel, Deckers, Edwards Lifesciences, Genmab

Dow Jones
·
Jul 24

Genmab, Abbvie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Dow Jones
·
Jul 24

Genmab A/S Stock Rises Wednesday, Outperforms Market

Dow Jones
·
Jul 23